Abstract:Major histocompatibility complex (MHC) class II molecules are membrane-anchored heterodimers that present antigenic peptides to T cells. Expression of these molecules in soluble form has met limited success, presumably due to their large size, heterodimeric structure and the presence of multiple disulfide bonds. Here we have used directed evolution and yeast surface display to engineer soluble single-chain human lymphocyte antigen (HLA) class II MHC DR1 molecules without covalently attached peptides (scDR1αβ). Specifically, a library of mutant scDR1αβ molecules was generated by random mutagenesis and screened by fluorescence activated cell sorting (FACS) with DR-specific conformation-sensitive antibodies, yielding three well-expressed and properly folded scDR1αβ variants displayed on the yeast cell surface. Detailed analysis of these evolved variants and a few site-directed mutants generated de novo indicated three amino acid residues in the β1 domain are important for the improved protein folding yield. Further, molecular modeling studies suggested these mutations might increase the protein folding efficiency by improving the packing of a hydrophobic core in the α1β1 domain of DR1. The scDR1αβ mutants displayed on the yeast cell surface are remarkably stable and bind specifically to DR-specific peptide HA306–318 with high sensitivity and rapid kinetics in flow cytometric assays. Moreover, since the expression, stability and peptide-binding properties of these mutants can be directly assayed on the yeast cell surface using immuno-fluorescence labeling and flow cytometry, time-consuming purification and refolding steps of recombinant DR1 molecules are eliminated. Therefore, these scDR1αβ molecules will provide a powerful technology platform for further design of DR1 molecules with improved peptide-binding specificity and affinity for therapeutic and diagnostic applications. The methods described here should be generally applicable to other class II MHC molecules and also class I MHC molecules for their functional expression, characterization and engineering.

Directed Evolution of Orthogonal Ligand Specificity in a Single Scaffold

A generic selection system for improved expression and thermostability of G protein-coupled receptors by directed evolution

Directed evolution of specific receptor–ligand pairs for use in the creation of gene switches

Directed Evolution of Estrogen Receptor Proteins with Altered Ligand-Binding Specificities.

Creating New Specific Ligand-Receptor Pairs for Transgene Regulation

LigEvolutioner, a New Strategy for Modification and Optimization of Lead Compounds in Receptor/Ligand Complexes

Directed evolution of a probe ligase with activity in the secretory pathway and application to imaging intercellular protein-protein interactions

Rational evolution for altering the ligand preference of estrogen receptor alpha

Strategy For The Directed Evolution Of A Peptide Ligase

Directed Evolution of Human Estrogen Receptor Variants with Significantly Enhanced Androgen Specificity and Affinity.

Computational structural-based GPCR optimization for user-defined ligand: Implications for the development of biosensors

Protocol for engineering binding domains to recognize ligand-bound receptors by using yeast surface display

Robust Generation of Lead Compounds for Protein-Protein Interactions by Computational and MCR Chemistry: P53/hdm2 Antagonists.

Molecular Determinants for Ligand Selectivity of the Cell-Free Synthesized Human Endothelin B Receptor

A Responsive Hidden Toehold to Enable Controllable DNA Strand Displacement Reactions.

Directed Evolution of Soluble Single-chain Human Class II MHC Molecules

Directed Evolution Using Stabilized Bacterial Peptide Display

Redesigning Enzyme Topology by Directed Evolution

Directed evolution of the multicopper oxidase laccase for cell surface proximity labeling and electron microscopy

Monitoring conformational changes in peroxisome proliferator-activated receptor α by a genetically encoded photoamino acid, cross-linking, and mass spectrometry

Enzyme engineering enables inversion of substrate stereopreference of the halogenase WelO5*